Skip to main content
Fig. 3 | Radiation Oncology

Fig. 3

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

Fig. 3

Ranking plot based simultaneously on efficacy (x-axis: SUCRA value of overall survival) and tolerability (y-axis: 1-SUCRA value of serious adverse events). SUCRA, surface under the cumulative ranking curves; SP, S-1-cisplatin; UP, uracil/tegafur (UFT)-cisplatin; PP, pemtrexed-cisplatin/carboplatin; EP, etoposide-cisplatin; PC, paclitaxel-cisplatin/carboplatin; NP, vinorelbine-cisplatin; DP, docetaxel-cisplatin; IC, irinotecan-carboplatin; GP, gemcitabine-cisplatin; MVP, mitomycin-vindesine-cisplatin; Cet, cetuximab

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us